# PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

> **NCT06390709** · — · UNKNOWN · sponsor: **Scipher Medicine** · enrollment: 1100 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Lab Collection Only

## Key facts

- **NCT ID:** NCT06390709
- **Lead sponsor:** Scipher Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-08
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390709, "PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06390709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*